In Reply We would like to thank Zhang and Han and Yang and colleagues for their appreciation of our work in the PEMBRO-RT trial.1 Both letters address the need for additional research on different radiotherapy modalities in combination with immunotherapy. We agree that our phase 2 study leaves many questions unanswered about the possibilities of this treatment combination. However, in 2019, use of pembrolizumab with or without the addition of chemotherapy became the standard of care in the first-line treatment of advanced non–small cell lung cancer, as pointed out by Yang and colleagues. Our pembrolizumab monotherapy setting enabled us to generate hypotheses without a possible interference of chemotherapy effects, especially in the subgroups with lower PD-L1 expression. Indeed, these hypotheses will need to be tested and translated to the new treatment landscape.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Theelen WSME, Baas P. Going Beyond Results of the PEMBRO-RT Trial—Reply. JAMA Oncol. Published online November 21, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.5034
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: